SIGFOX
13.3.2020 10:48:06 CET | Business Wire | Press release
In partnership with Energo Capital, a digital venture capital company, operating across Russia and the Baltics, Sigfox , the world’s leading Internet of Things (IoT) service provider and first global 0G network operator, launches its 0G network for IoT in the Russian Federation. The newly formed Sigfox Russia will be using ultra-long coverage base stations to create a nationwide 0G network, covering more than 85% of the population, large industrial sites, transport hubs and corridors. This communication network will allow millions of sensors, metering and other devices to “connect,” through low-power, simple and inexpensive radio modules.
Today, Sigfox operates in more than 70 countries on 5 continents with more than 1.1 billion people, transmitting 26 million messages daily from 15.4 million IoT devices.
“Russia is a key country not only because of market size, which is predicted to grow to $7.6 billion in 2022 ,” notes Bertrand Ramé, Senior Vice President Expansion & Partner Management at Sigfox . “For the global economy, Russia is also very important for the digitalization of thousands of kilometers of railway corridors within the Belt and Road Initiative, all the way through the Baltics and Poland to Western Europe. Sigfox as the proven leader in transportation and logistics IoT services is very well positioned to help fulfill this challenge. For the countries of the region, Russia is the technological leader in the IoT field and will drive regional digitalization. Within the global digital ecosystem, Russia is acknowledged for creating and delivering innovative IoT technologies and products ”.
The availability of the global 0G communication standard in Russia will contribute to the implementation of the National “Digital Economy of the Russian Federation” program, will stimulate the development of the Russian digital ecosystem and will reduce the costs of implementing IoT solutions by adapting global best practices.
Sigfox’s open communication standard will provide localization and make available international IoT solutions, while also strengthening the export potential of Russian companies developing and manufacturing IoT technologies and products.
Midterm plans also include providing coverage in areas where it is impossible to create terrestrial 0G communication networks such as Taiga, the Northern Sea Route, etc. by using the future ELO nanosatellite constellation, deployed and operated by Sigfox in partnership with Eutelsat.
Sigfox Russia is the exclusive distributor of Sigfox in Russia and offers comprehensive solutions including the Sigfox’ 0G network, smart devices and platforms.
“We saw a significant demand for Sigfox solutions in transport and logistics, infrastructure and utilities and commercial real estate sectors. We have designed our network deployment plans based on the market potential, ” says Eric Brisset, CEO of Sigfox Russia . “It is possible that we may accelerate our plans. This is due to an increase in the number of requests from companies from other market segments, as well as significant interest from potential partners who would like to be part of Sigfox’ global business. ”
0G technology
The Sigfox global 0G network has been designed to connect the physical world with the digital universe and power industry transformation. It is a simple, open and energy-efficient communication technology for the Internet of Things, providing an ultra-low cost for connecting and operating devices. The use of an unlicensed radio range, an ultra-narrowband communication standard, simple and energy-efficient devices with a lifespan of more than 12 years and a cost of not more than $1.5, a roaming-free global space, allow digitalization of objects of the physical world that were previously impossible or unprofitable to connect to communication networks.
Services
Sigfox offers solutions for various segments of the economy: transport, logistics and supply chain, commercial real estate management, manufacturing, retail, agriculture, ground handling of airports, company insurance, energy and utilities, social and municipal sectors, etc.
Sigfox services are used by international companies such as Total, Airbus, Michelin, Danone, Bosch, PSA and many others to create new sources of revenue, increase operational efficiency, improve customer service, reduce risks and increase security. Among recent significant contracts for connecting hundreds of thousands of devices, contracts have been signed with DHL, the global leader in logistics and express delivery, and the Japanese gas distribution operator NICIGAS.
Global ecosystem
Sigfox offers Russian device and platform manufacturers an opportunity to join its global ecosystem of suppliers by participating in Starter and Build programs. Using these programs, developers gain an idea of each stage of product creation and can access technical documents, online instructions and assistance on certification.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 70+ countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200313005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
